The analysis of relationships between the cost-sharing payments arrangements for prescription-only pharmaceuticals and the value of prescription-only pharmaceuticals consumptionThis paper analyzes patient cost-sharing arrangements for prescriptiononly pharmaceuticals in the 27 European Union (EU) member states. These arrangements are matched to the value of prescription-only pharmaceuticals consumption in these countries to search for relationships. Data are collected based on a literature review nd are analyzed using a combination of qualitative and quantitative research techniques. The results indicate no relationship between the cost-sharing payments arrangements for prescription-only pharmaceuticals and the value of prescription-only pharmaceuticals consumption. The lack of statistically significant results leads to conclusion that the potential implementation of the cost-sharing scheme for prescription-only pharmaceuticals can not base solely on the other countries experience. The different motivation for implementing the cost-sharing should be considered together with the following aspects: willingness to pay, potential effects on equity and detailed assessment of advantages and disadvantages of different pharmaceuticals usage.
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.